MX2008004578A - Probiotics to influence fat metabolism and obesity - Google Patents
Probiotics to influence fat metabolism and obesityInfo
- Publication number
- MX2008004578A MX2008004578A MXMX/A/2008/004578A MX2008004578A MX2008004578A MX 2008004578 A MX2008004578 A MX 2008004578A MX 2008004578 A MX2008004578 A MX 2008004578A MX 2008004578 A MX2008004578 A MX 2008004578A
- Authority
- MX
- Mexico
- Prior art keywords
- product
- obesity
- probiotics
- food
- mice
- Prior art date
Links
- 230000000529 probiotic Effects 0.000 title claims abstract description 76
- 239000006041 probiotic Substances 0.000 title claims abstract description 76
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 76
- 208000008589 Obesity Diseases 0.000 title claims abstract description 34
- 235000020824 obesity Nutrition 0.000 title claims abstract description 34
- 230000036740 Metabolism Effects 0.000 title description 11
- 230000004060 metabolic process Effects 0.000 title description 11
- 230000035786 metabolism Effects 0.000 title description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 40
- 241000894006 Bacteria Species 0.000 claims abstract description 33
- 235000013305 food Nutrition 0.000 claims abstract description 31
- 102000004877 Insulin Human genes 0.000 claims abstract description 20
- 108090001061 Insulin Proteins 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000036186 satiety Effects 0.000 claims abstract description 16
- 235000019627 satiety Nutrition 0.000 claims abstract description 16
- 230000004584 weight gain Effects 0.000 claims abstract description 13
- 235000019786 weight gain Nutrition 0.000 claims abstract description 13
- 230000035945 sensitivity Effects 0.000 claims abstract description 10
- 230000037406 food intake Effects 0.000 claims abstract description 9
- 235000012631 food intake Nutrition 0.000 claims abstract description 8
- 235000016709 nutrition Nutrition 0.000 claims abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
- 230000037149 energy metabolism Effects 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims abstract description 4
- 210000004080 Milk Anatomy 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 229940039695 Lactobacillus acidophilus Drugs 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 240000004403 Lactobacillus casei Species 0.000 claims description 4
- 229940017800 Lactobacillus casei Drugs 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 229940009289 Bifidobacterium lactis Drugs 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 abstract description 6
- 229940039696 Lactobacillus Drugs 0.000 abstract description 6
- 230000002708 enhancing Effects 0.000 abstract 1
- 235000019553 satiation Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 57
- 239000000902 placebo Substances 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 235000020167 acidified milk Nutrition 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 230000036541 health Effects 0.000 description 14
- 210000000936 Intestines Anatomy 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000003860 storage Methods 0.000 description 9
- 206010012601 Diabetes mellitus Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 210000000577 Adipose Tissue Anatomy 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 229940107161 Cholesterol Drugs 0.000 description 6
- 102000007156 Resistin Human genes 0.000 description 6
- 108010047909 Resistin Proteins 0.000 description 6
- 235000003642 hunger Nutrition 0.000 description 6
- 210000000579 Abdominal Fat Anatomy 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 210000000987 Immune System Anatomy 0.000 description 4
- 206010022489 Insulin resistance Diseases 0.000 description 4
- 230000000975 bioactive Effects 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 102100001080 APOA4 Human genes 0.000 description 3
- 102000011690 Adiponectin Human genes 0.000 description 3
- 108010076365 Adiponectin Proteins 0.000 description 3
- 102100009886 CA3 Human genes 0.000 description 3
- 101710040959 CA3 Proteins 0.000 description 3
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 235000020825 overweight Nutrition 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 206010062060 Hyperlipidaemia Diseases 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 101710023485 RETNLB Proteins 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 150000002516 isoflavones Chemical class 0.000 description 2
- 229930012948 isoflavones Natural products 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2S,3S,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[(2R,3S,4R,5S,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,4R,5S,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan zwitterion Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 101710041485 ACTR6 Proteins 0.000 description 1
- 101710003225 ADIPOQ Proteins 0.000 description 1
- 101700081070 APOA4 Proteins 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 101710014084 CFD Proteins 0.000 description 1
- 102000003706 Complement Factor D Human genes 0.000 description 1
- 108090000059 Complement Factor D Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 210000003608 Feces Anatomy 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108009000020 Glucose Homeostasis Proteins 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hibiscus acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940004208 Lactobacillus bulgaricus Drugs 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 229940059406 Lactobacillus rhamnosus GG Drugs 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 101700083808 THRSP Proteins 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 230000001234 nutrigenomic Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 230000000291 postprandial Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020192 probiotic milk Nutrition 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 230000028201 sequestering of triglyceride Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000476 thermogenic Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
Use of probiotic bacteria for the manufacture of a food product, feed product, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product to be used for controlling weight gain, preventing obesity, increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, improving energy metabolism, enhancing insulin sensitivity, treating obesity and treating insulin insensitivity. The probiotic bacteria is at least one ofLactobacillus caseiF19 (LMG P-17806),Lactobacillus acidophilusNCFB 1748 oxBifidobacterium lactisBb 12.
Description
P OBJECTIVES TO INFLUENCE FAT METABOLISM AND OBESITY
Field of the Invention The invention relates to the use of probiotic bacteria for the manufacture of a food product, animal food product, dietary supplement, nutritional product, natural remedy, active pharmaceutical formulation and nutritional product to be used to control weight gain, prevent obesity, increase satiety, prolong fatigue, reduce food intake, reduce fat deposition, improve energy metabolism, increase insulin sensitivity, treat obesity and treat insensitivity to insulin.
Background of the Invention Interest in the use of foods to influence health is rapidly increasing among researchers, health professionals and in the food industry. Metabolic syndrome that includes obesity, abdominal fat storage and type 2 diabetes is one of the main threats to human health and well-being. Nowadays, more people are dying to eat too much than the number of people who die by eating little. In this way, the possibility of reducing the risk of obesity and storage of body fat is of great value in a global health perspective and the possibility of developing food products in this area is of great interest for the food industry. The food industry has already responded to this demand by developing products with low energy density for example products with low fat content and low carbohydrate content. The possibilities of finding bioactive components, of natural origin in the food or that it is possible to add them, that influence the risk of obesity, fat metabolism, glucose metabolism and satiety opens a new possibility for the industry to develop functional foods with effects to health documented. Recent studies have been published showing a correlation between the consumption of high levels of calcium in milk and a low body mass index
(BMI, for its acronym in English). Today, the conclusion that calcium in milk, and dairy products, decreases the risk of obesity, storage of body fat and insulin resistance has been drafted in a variety of review articles. Calcium by itself does not seem to have these properties and it has been speculated that in addition to calcium there is a need for bioactive components that are present in milk.
Probiotics are defined by ILSE (International Institute of Life Sciences) as "aggregated microorganisms with a beneficial effect on health". Probiotics are commonly used in foods, animal food products and dietary supplements because of their influence on the health, infection and the immune system of the intestine. It has also been shown that some strains of probiotics, but not all those studied, influence the level of cholesterol in the blood and recently the possibility of lowering blood pressure has been discovered through the use of dairy products fermented by lactic acid bacteria. proteolytic In this way, the interest in probiotics is broad and the central role of the intestinal flora for the health and well-being of the intestine and the immune system is firmly established. During the last years, techniques have been developed, frequently referred to as genomics and nutrigenomics. These techniques allow new unique possibilities to study the influence of food, nutritional components and probiotics on health and well-being. The techniques allow the study on the expression of genes of thousands of genes simultaneously. In this way, new and unexpected areas for health effects can be found and the mechanism behind an effect on health can be suggested. The basis for this application are the studies on man and mice that interestingly show that a probiotic product influences satiety, decreases fat storage and the risk of obesity. The possible mechanisms behind the observed effect were explained from studies of gene expression after consumption of probiotic products.
Description of the Prior Art Metabolic functions that contribute to overweight, metabolic syndrome and the risk of type II diabetes have been described and the connection between general nutrition and those diseases is also well known. However, there is a need for intervention studies based on diets to establish the role of individual foods and a group of foods in decreasing the risk of developing those diseases. In studies in this area, there has been a focus on energy density, fat and carbohydrates. An important factor in the metabolic syndrome is glucose metabolism that includes insulin sensitivity. There is a connection between the deposition of body fat, insensitivity to insulin and overweight. There is also a connection for satiety and fatigue.
The interactions and relationships between these functions are complex and it is difficult to identify the exact sequence of events that lead to health or illness. A variety of genes and their corresponding proteins that are involved in energy homeostasis have been described. Adipose tissue synthesizes a variety of proteins with structural similarity to cytokines and therefore these proteins are called adipokines. Some of these are also synthesized in the intestine or the synthesis is regulated from the intestine. The nuclear receptor PPAR-gamma is involved in the synthesis of for example adiponectin and the synthesis is associated with the uptake of calories and the signaling of leptin. The increased synthesis of adiponectin improves insulin sensitivity by increasing the transport, oxidation and dissipation of fatty acids in skeletal muscle and by increasing the sensitivity of the hepatocyte to insulin. Another factor derived from adipocytes nutritionally regulated that influences insulin sensitivity is resistin. Circulating levels of resistin are increased in obesity while treatment of mice with resistin resulted in increased glucose production and impaired insulin action. In this way, resistin has a function in glucose homeostasis and acts as an antagonist for the action of insulin, giving rise to insulin resistance. Proteins such as resistin are also expressed in the gastrointestinal tract (14). The protein apolipoprotein A-IV is secreted by the small intestine in humans and in rodents. The synthesis is stimulated by the uptake of fat and the protein is probably involved in the inhibition of food intake after the ingestion of fat. Studies have shown that apolipoprotein A-IV is probably involved in both short-term and long-term regulation of food intake. Hooper et al. (11) studied the expression of genes in the intestine of mice exposed to Bacteroides thetraiotaomicron. They concluded that the experiments show the essential role for the interaction between the microflora of the intestine and the host. No effects on energy metabolism or obesity were reported. The influence of probiotics on the expression of genes in the mucosa of the small intestine has been studied for Lactobacillus rhamnosus GG (8). His conclusion is that the administration of Lactobacillus GG is associated with a complex genetic response. The main responses observed are the effects on the immune system, inflammation, apoptosis, growth and differentiation of cells, cell adhesion and transcription and signal transduction. No effects are reported on the metabolism of energy, fat, glucose or insulin. In an oral presentation by. de Vos, at the 4th Dairy Products conference in NIZO in 2005, the influence of lactobacilli for example L. plantarum 299v on the expression of genes in the intestine was presented and the conclusion was that the effect on The expression of genes of the different strains varies considerably. No effect on energy or fat metabolism was reported. Some articles have been published that connect intestinal flora with weight gain and fat storage. Backehed et al. (7) studied the importance of normal intestinal flora for weight gain and storage of body fat. It has been shown that conventionalized gnotobiotic mice with a normal microbiota increased their body fat by 60% and increased insulin resistance during a 14-day feeding period despite reduced feed uptake. A suggestion is presented on how the microbiota can influence the storage of triglycerides. In this way, it is known that the normal intestinal microbiota influences the metabolism of fat, however until this investigation it was not known if the normal flora could be modified in regard to fat metabolism.
Ali and colleagues (2, 3) have studied the influence of soy isoflavones with or without probiotics to influence cholesterol metabolism and fat deposition and discovered that the probiotics used had no influence on cholesterol or fat deposition. Another research reference has shown that some strains of probiotics can influence the level of cholesterol in the blood (1, 13). This and other studies comparing probiotic strains show that the different strains of probiotics have different characters and it is important to select the correct strains for specific effects on health. In the PCT patent application WO 04/014403 (15), the use of probiotics to reduce the amount of monosaccharides and disaccharides in a food and consequently to treat or prevent the risk of obesity is described. In US Pat. No. 6,698,057 Bojrab (4) a composition of yoghurt bacteria for example Lactobacillus bulgaricus and "Streptococcus thermophilus for the treatment of gastrointestinal disorders, hyperlipidemia and autoimmune diseases has been patented and in US Pat. No. 6,641 808 Boj rab (5) describes the use of the same composition also for the treatment of obesity. This invention is also described in European Patent Application No. 1 177 794 (6). The patents / applications have a long description about the influence of probiotics on health, infection and immunity of the intestine but the only experiment presented that confirms the influence on obesity is an individual feeding test in a person. The use of green tea or green tea extracts in combination with a variety of bioactive and probiotic components for weight loss has been patented by Gorsek in U.S. Patent Nos. 6 383 482 (9) and 6 565 847 (10). In both patents, the main active components are green tea and bioactive components, while probiotics are added as part of the basic composition. In U.S. Patent No. 6,808,703 and Japanese Patent Application No. 2001-292728 (16) there is disclosed a way of preparing a food for the treatment of obesity containing yeasts, enterobacteria, lactic acid bacteria, oligosaccharides and vegetable fiber. No examples or claims are presented regarding the treatment of obesity.
Description of the Invention One objective of the invention is the use of probiotic bacteria for the manufacture of a food product, food product for animals, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal products to be used to control the gain of weight, prevent obesity, increase satiety, prolong fatigue, reduce food intake, reduce fat deposition, improve energy metabolism, increase insulin sensitivity, treat obesity and treat insulin insensitivity. This objective is achieved insofar as the probiotic bacteria are selected from the group consisting of lactic acid bacteria especially Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium lactis and more preferably Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748 and Bifidobacteriu-Ti lactis Bbl2 (bacteria are deposited in the LMG culture collection in Gent, available from the NCFB culture collection and from Chr. Hansen Company DK, respectively). The strains will be referred to hereafter as LMG P-17806, NCFB 1748 and Bbl2. Lactobacillus casei F19 (LMG P-17806),
Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bbl2 are well characterized and the strain LMG P-17806 and its use is previously patented (WO 99/29833). All three strains survive well in food products and during passage through the intestine.
The impact of the invention is of considerable importance since the common lifestyle of today often results in an excess of food intake leading to an increased risk for the metabolic syndrome that includes obesity, abdominal fat deposition and type II diabetes. Type II diabetes is caused by low insulin sensitivity or insulin resistance. This threat to human health is continually increasing in all age groups throughout the world. Lactobacilli as probiotics are accepted as a food product and food product for animals, natural product, dietary supplements and in natural remedies, pharmaceutical active formulations and medicinal products. They are easy to use in those supply systems and can be easily consumed on a daily basis. Regular consumption of these bacteria will help control weight gain, prevent obesity, increase satiety, prolong the fatigue, reduce food intake, reduce fat deposition, improve energy metabolism, increase insulin sensitivity , treat obesity and treat insensitivity to insulin and consequently the risk of diseases included in the metabolic syndrome. The following studies are included in the invention: A study has shown in a promising way that a probiotic product can decrease the weight gain in humans. Additional studies have shown that probiotics administered to man reported higher satiety and had a more prolonged satiety than individuals who were given the same acidified milk without probiotics or placebo. Mice given probiotics had lower total energy uptake, less fat deposition in the adipose tissue and a lower total weight gain than the individuals who were not given probiotics. The studies of gene expression confirm that the probable mechanism behind the observed effects is an influence on a group of genes involved in the metabolism of energy, fat, sugar and insulin and in fatigue.
EXAMPLES 1) Regulation of weight in humans In a double-blind placebo controlled study, humans were given either an acidified milk containing probiotics (LMG P-17806 and NCFB 1748) or the same acidified milk without probiotics or a tablet of calcium. The groups consisted of 15, 14 and 10 people respectively. The probiotic bacteria were added to the product in a final concentration 5xl0E7 CFU / ml and the number of bacteria was stable in the product during the experimental time. The participants were fed 2x2.5 di of the product each day. The people included were slightly overweight (BMI 25-30). The objective of the test was to study the effects of probiotics on cholesterol metabolism and weight gain was taken as a control measure. No advice was given regarding weight control but all participants volunteered for a weight reduction treatment after the test. The bacteria survived passage in the intestine and increased the number of lactobacilli found in the faeces of the participants by a factor of 5. After 4 weeks, there was a surprising but significant difference in weight gain between the three groups. The main figure for weight gain was 0.25 kg in the group that received the probiotic product, 0.75 kg in the group that received the acidified milk without probiotics and 1.4 kg in the group that received the tablet. See Figure 1.
2) Satiety and satiety in humans In a double-blind placebo-controlled study, humans were given either an acidified milk containing probiotics at two different doses in a placebo no. 1 which consisted of the same acidified milk without probiotics or a placebo no. 2 which consisted of acidified milk without any lactic acid bacteria at all. The probiotic microorganisms, LMG P 17806, NCFB 1748 and Bb 12, were added to the final product in a final concentration of lxlOE6 CFU / ml and 5xlOE7 CFU / ml of each strain. After a standard controlled breakfast, which included 3 di of any of the four products, participants were asked to indicate satiety and hunger on a VAS (Visual Analogue Scale) scale directly after feeding and continuously every half hour for 4 hours. Completely, the 10 people were included in the study and each participant was administered the four products but on different occasions and the relative differences were calculated. Directly after the food there was a slight difference in the satiety records between the products. Milk acidified with probiotics at a concentration of 5xlOE7 CFU / ml and lxlOE6 gave the highest records (relative VAS record 6.6 and 6.4 respectively) and placebo did not. 1 had an intermediate record (relative VAS record 6.2) and placebo no. 2 had the lowest record (relative VAS record 5.9). The satiety records fell after 3.5 hours to 3.1, 3.0, 2.5 and 2.2 respectively. The difference was small but the difference between the products persisted and an influence was observed on the fatigue for the probiotic product with two different concentrations of bacteria. With regard to hunger, the opposite situation could be observed, that is, probiotic products provided a lower hunger registry than the two placebo products. Directly after feed, the two probiotic products resulted in 0.4 hunger records for both products on the VAS scale, no placebo. 1 was intermediate (VAS record 0.9) and placebo was not. 2 provided a VAS registry on hunger in 1.1. After 4 hours, the figures were 6.0, 6.2, 7.0 and 6.9 respectively. After the previous standard breakfast and the four hours when data on satiety and hunger were observed, participants were offered a standard lunch. Participants were asked to eat until they were pleasantly satisfied and try to get the same level of fullness after each different breakfast. After eating the probiotic products, the energy intake at lunch was 3690 KJ for the product with high level of probiotics, it was 3810 for the product with low level of probiotics. For the placebo no.
1 was 3850 and for placebo no. 2 was 3995. This shows that probiotic products can reduce energy uptake in a postprandial food after eating the probiotic products as part of the breakfast.
3) Mice food uptake mice with normal flora of the Swiss Webster strain were given acidified milk containing either LMG P-17806 or NCFB 1748 or a placebo product with the same composition but without probiotics for 10 days . The mice had between 6 and 8 weeks when the administration was started. The groups that were given probiotics contained 7 mice in each group and the placebo group consisted of 5 animals. The probiotic microorganisms were added to the products in a final concentration of lxlOEd CFU / ml and the number of bacteria was stable in the product during the feeding period. The mice were given two standard daily doses of the products, one by means of the forced oral feeding of 1 ml and one by means of a sublingual injection. Both probiotic bacteria survived passage in the intestine and were present in significant numbers in the small and large intestine of the mice. In addition to the probiotic products and the placebo product, the mice had access ad libi tum to a diet of purified ingredients (D12450B from Research Diets Inc., New Jersey, USA). The daily uptake of food was compared between the two groups of mice that received Lactobacillus strains against the group of mice that received placebo. The products were well tolerated by the mice. During the second part of the feeding period, the uptake of feed was significantly reduced in the groups of animals given probiotics compared to the group that received the placebo product. See Figure 2.
4) Abdominal fat storage in mice Mice with normal flora were given either an acidified milk probiotic product containing LMG P-17806 or a placebo product with the same composition but without probiotics or were kept as a group of control to which they were administered the same food as the other two groups but without the acidified milk. The strain of mouse selected was C57B16 (Charles River) which is sensitive to obesity induced by a diet. The number of animals included in the different groups was 15 in each of the groups given acidified milk and 3 in the control group. The mice were introduced to the study when they were 9 weeks old. The number of probiotic bacteria in the product was lxlOEd CFU / ml and the mice were allowed to eat the product ad libi tum, 5 days a week, for a total number of 12 weeks. For rapid weight gain, the mice were fed a high-fat diet (D 12309 from Research Diets Inc. New Jersey, USA containing 36% fat for the first 5 weeks and then D12492 (35% fat ) of the same company during the remaining weeks of the test). After 12 weeks, the mice were sacrificed and data on weight gain, feed intake and amount of abdominal fat were analyzed. Mice given an acidified milk product gained less weight than control mice that did not receive any acidified milk. Mice given milk acidified with probiotics also had lower abdominal fat storage compared to the group that received acidified milk without probiotics and the control group that did not receive any acidified milk at all.
) Gene expression in mice Germ-free and normal-flora mice of the Swiss Webster strain were given acidified milk containing either LMG P-17806 or NCFB 1748 or a placebo product with the same composition but without probiotics for 10 days. The mice were between 6 and 8 weeks old when the administration was started. The groups given probiotics contained 6 mice in each group and the placebo group consisted of 4 animals. The probiotic microorganisms were added to the products in a final concentration of lxlOEd CFU / ml and the number of bacteria was stable in the product during the feeding period. The mice were administered the product daily by means of forced feeding by the oral route. During the study, mice had access ad libi tum to a diet of purified ingredients (D12450B from Research Diets Inc., New Jersey, USA). Both probiotic bacteria survived passage in the intestine and were present in significant numbers in the small and large intestine of the mice. The mice were sacrificed and the expression of genes in the small intestine was analyzed by means of a microarray technology of oligonucleotides. In addition to the expected effects on the immune system, it was discovered that the unexpected effects on the expression of a variety of genes involved in energy metabolism and homeostasis were different in the placebo group compared to the two groups of probiotics. Among the genes that show a significant change in expression were Scdl, Acrp30, Adn, Thrsp, Car3 and Apoa-4, all of which were up-regulated in the probiotic groups and Retnlb which was down-regulated in the probiotic groups, compared to the placebo group. The differential gene expression pattern was very similar for the probiotic strains used. The differential expression of the adipsin (Adn), adiponectin (Acrp 30), carbonic anhydrase 3 (Car3) and resistin as beta (Retnlb) genes in the germ-free mice was confirmed by the quantitative Real Time PCR technique , see Figure 3. Figure 4 shows the expression levels of apolipoprotein A-IV (Apoa4) in mice colonized with normal flora as verified by means of the quantitative Real Time PCR approach.
6) Dosage The total dosage of the individual strains of probiotic bacteria in the different experiments described above was lxlOEd-lxlOE9 CFU (experiments with mice) and 2.5xlOE8-2, 5xlOE10 (experiments in humans). It is necessary that this dosage be administered in a portion or as a daily dose which means that for example a beverage for human use that is consumed in quantities of 200-500 ml needs to contain O, 5xlOE6-l, 25xlOE8 CFU / ml of the individual strain to be effective and a capsule needs to contain the total amount of bacteria in approximately 1 g of the content in the capsule ie lxlOEd-2, 5xlOE10. For the highest concentrations of bacteria, it is necessary for the bacteria to be concentrated by means of freeze drying or spray drying.
7) Product preparation Probiotic bacteria have to be added to products based on milk, cereals or fruits. Bacteria were added as a concentrate for example lyophilized and survival was analyzed in all three matrices. Survival was very good in milk-based and cereal-based products. In the fruit-based product, survival is influenced by the type of fruit. Since it is necessary to be careful with a lyophilized powder in regard to water activity and exposure to oxygen. The results of the generation of products can be seen in table 1. Probiotic bacteria can also be added to milk-based products together with other lactic acid bacteria for the production of different kinds of cultivated products. In this environment, the probiotic bacteria can multiply and adjust well to the acidic environment providing a good survival also at the final low pH in those products. The results of the generation of products can be seen in table 1.
Table 1. Survival of probiotic bacteria in different product matrices measured as million CFU / g. The products were stored at 8 ° C.
References: 1) Agerholm, 1., M.l. Bell, G.k. Grunwald and A. Astrup. 2000. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur. J. Clin. Nutr. 54: d56-d60. 2) Ali A. A., I. A. Mohamed, C. T. Hansen, T. Wang, M. T. Velasquez and S. J. Bhathena. 2002. Effect of probiotics and isoflavones on metabolic parameters in a genetic model of obesity and diabetes. FASEB J. 16: p A1014. 3) Ali. A. A., M. T. Velasquez, C. T. Hansen, A. I. Mohamed and S. J. Bhathena. 2004. Effect of soybean isoflavones, probiotics and their interactions on the metabolism and endocrine system in an animal model of obesity and diabetes. J. Nutritional Bioch. 15: 563-590. 4) Bojrab G., 2000. Composition and method for treatment of gastrointestinal disorders and hyperlipedemia. U.S. Patent No. 6 696 057 5) Bojrab G., 2000. Composition for treatment of obesity. U.S. Patent No. 6,641,808. 6) Bojrab G., 2001. Composition, of L. bulgaricus and S. thermophilus, for the treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases, and obesity. European Patent Application No. 1 177 794. 7) Báckehed F., H Ding, T. Wang, L. V. Hooper, G. Y. Koh, A. Nagy, C. F. Semenkovich and J. I. Gordon. 2004. The gut microbiota as an environmental factor that regulates fat storage. PNAS 101: 15718-15723. 8) Di Caro S., H. Tao, A. Grillo, C. Elia, G. Gasbarrini, A. R. Sepulveda and A. Gasbarrini. 2005. Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Digestive and Liver Disease 37: 320-329. 9) Gorsek W. F. 2000. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophane, glucomannan, picolinate and Lactobacillus. U.S. Patent No. 6 383 482. 10) Gorsek W. F., 2002. Thermogenic weight management composition. U.S. Patent No. 6 565 847. 11) Hooper L.V., M Wong, A. Thelin, L. Hansson, P.G. Falk and J.I. Gordon. 2001. Molecular analysis of commensal host-microbial relationship in the intestine. Science 291 (5505): 881-884. 12) Park H. O., Y. B. Bang, H. J. Joung, B. C. Kim and H. R. Kim. 2004. Lactobacillus KTCK 0774BP and acetobacter KCTC 0773BP for treatment or prevention of obesity and diabetes mellitus. U.S. Patent No. 6 808 703. 13) Pereira D. I. and G. R. Gibson. 2002. Effects of probiotics and prebiotics on serum lipid levéis in humans. Crit. Rev. Biochem Mol Biol. 37: 259-281.
14) Steppan C. M., S. Balley, S. Bath, E. J. Brown, R. R. Banerjee, C. M. Wright, H. R. Patel, R. S. Ahlma and M.
Random. 2001. The hormone resistine links obesity to diabetes. Nature 409: 307. 15) Song S.H., S. K. Kang, j.H. Kim and. H. Park and H. O. Park 2002. Microorganisms for ihibiting obesity and diabetes mellitus. PCT patent application WO 04/014403. 16) Yanagida F. and K. Sano. 2000. Obesity preventative food. Japanese patent application 2001-292728.
Claims (3)
- CLAIMS 1. Use of probiotic bacteria for the manufacture of a food product, food product for animals, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product to be used to control weight gain, prevent obesity, increase the satiety, prolong fatigue, reduce food intake, reduce fat deposition, improve energy metabolism, increase insulin sensitivity, treat obesity and treat insulin insensitivity, where probiotic bacteria are at least minus one of Lactobacillus casei F19
- (LMG P-17806), Lactobacillus acidophilus NCFB 1748 or Bifidobacterium lactis Bbl2. 2. The use according to claim 1 in a composition comprising at least one of milk, cereals or fruit or compositions derived therefrom.
- 3. Use in accordance with the claim 1 in a product used as a food product, food product for animals, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0502214-0 | 2005-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008004578A true MX2008004578A (en) | 2008-09-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006299956B2 (en) | Probiotics to influence fat metabolism and obesity | |
Thushara et al. | Cardiovascular benefits of probiotics: a review of experimental and clinical studies | |
Aggarwal et al. | Probiotics and their effects on metabolic diseases: an update | |
CN102076360B (en) | Probiotics, secretory immunoglobulin A and inflammation | |
EP2442814B1 (en) | Bifidobacteria for treating diabetes and related conditions | |
Kalantzopoulos | Fermented products with probiotic qualities | |
TWI594758B (en) | Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof | |
KR20210013352A (en) | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions | |
KR20190116248A (en) | New Probiotic Bifidobacterium Strains | |
EP2459203A1 (en) | Lactic acid bacteria and bifidobacteria for treating endotoxemia | |
EP3909589B1 (en) | Liquid probiotic-herbal preparation | |
US20120027737A1 (en) | Use of probiotics to ameliorate diet-induced insulin resistance | |
US10022407B2 (en) | Use of a lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance | |
EP4364583A1 (en) | Composition comprising three lactobacillus sp. strains, and use thereof | |
CN109715181B (en) | Bacteria | |
MX2008004578A (en) | Probiotics to influence fat metabolism and obesity | |
AU2022302837B2 (en) | Composition comprising three lactobacillus sp. strains, and use thereof | |
Varzakas et al. | 12 Functional Dairy Foods and Flora Modulation | |
Singhal et al. | Therapeutic Effects of Gut Microbiota on Metabolic Syndrome: A Patent Review | |
Prapaipat et al. | Probiotic property and biological activities of Bifidobacterium animalis subsp. lactis TISTR 2591 isolated from Thai population | |
CN117838737A (en) | Bifidobacterium breve 207-1 and application thereof in regulating lipid metabolism direction | |
CN118203603A (en) | Metagen and application thereof in regulating lipid metabolism direction | |
Workouts et al. | Probiotic Roundup | |
Sharma et al. | 13 Probiotics and Its Efficacy Assessment in Diabetic Intervention |